Emil Kuriakose, MD, has been named chief medical officer of Terns Oncology, a division of clinical-stage biopharmaceutical company Terns Pharmaceuticals.
Dr. Kuriakose will step into the role May 1, according to a March 27 news release. He joins Terns Oncology from Calithera Biosciences, where he served as chief medical officer and led two mid-stage clinical programs.
Dr. Kuriakose also has experience leading the global clinical program at the Cambridge, Mass.-based Novartis Institutes for BioMedical Research and as medical director of Novartis Oncology, where he designed and executed oncology trials.